New study tracks ABRYSVO Vaccine's power to shield seniors from severe RSV
NCT ID NCT06077968
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study examines how effective Pfizer's ABRYSVO vaccine is at preventing severe RSV infections in adults aged 60 and older. Researchers will analyze existing health records from routine doctor visits over several years, without actively enrolling participants. The goal is to understand how long protection lasts and whether a booster dose is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUSES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.